查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
CAR-T 融資：創投、IPO、授權協議、業務聯盟、併購交易（2024 年）
市場調查報告書
商品編碼
1443436

CAR-T 融資：創投、IPO、授權協議、業務聯盟、併購交易（2024 年）

CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024
出版日期: | 出版商: BioInformant | 英文 207 Pages | 訂單完成後即時交付

價格
簡介目錄

執行摘要

CAR-T 產業的資金正在飆升，而不是增加。 最初，這種趨勢很微妙，但隨著 Kymriah、Yescarta、Tecartus、Breyanzi、Abecma 和 Carvykti 等 CAR-T 療法進入市場並引發融資熱潮，這種趨勢正在增強。 近年來，CAR-T 新創公司從渴望利用這一再生醫學趨勢的投資者那裡獲得了充足的資金。

全球有超過 170 家公司參與 CAR-T 產品和治療的開發。 這些 CAR-T 療法公司正在開發近 970 種早期和晚期療法。 這些公司還擁有令人印象深刻的 98 份業務合作協議，以推進各種 CAR-T 產品候選者的開發。 其中，33個商業合作項目已揭露財務條款，交易總額達217億美元。 如果算上未揭露條款的商業合作項目，這98個商業合作項目的總價值高達630億美元。

在過去十年中，CAR-T 公司已獲得 67 億美元的風險投資，使他們能夠投資於基礎設施和產品管道。 同期，CAR-T 公司透過 IPO 融資籌集了 58 億美元，用於加強其技術基礎、臨床試驗項目和企業努力。

在這個擁有超過417,801 項專利記錄和4,024 項授權專利的新興行業中，大型製藥公司正在尋求透過現有專利持有者的許可權進入CAR-T 領域。該行業正在變得越來越強大。 因此，過去十年CAR-T授權交易的總價值為39億美元，預計未來十年這一總額將大幅成長。

在本報告分析的各種類型的融資中（包括 CAR-T 行業的 IPO 和許可協議、業務聯盟、戰略合作夥伴關係、聯合開發協議和併購交易），併購交易是最大的財務交易過去10 年價值高達959 億美元。

對於年輕的 CAR-T 產業來說，透過這些具有報告財務條款的各種交易籌集了超過 1,282.5 億美元的資金，這是一項了不起的成就。 此外，84項CAR-T許可協議中的59項、98項業務合作協議中的65項以及27項併購交易中的11項均未揭露交易金額。 因此，如果粗略計算所有未公開金額的交易，總金額將高達2400億美元。

目前美國 FDA 核准了六種 CAR-T 療法：

  • Tisagenlecleucel-T (Kymriah)
  • Axicabtagene ciloleucel (Yescarta)
  • Brexcabutagene autoleucel（Tecartus）
  • Rhizocabutadiene Malaleucel (Breyanzi)
  • Idecabtagene viclucel (Abecma)
  • Tirtacabutagene autoleucel（Carvykte）

上述許多 CAR-T 療法已獲得其他監管機構（如歐洲、中國、印度）的批准。 由於 CAR-T 審批在全球範圍內正在加速，因此該清單並不詳盡。 根據 ClinicalTrials.gov 統計，目前有 706 個 CAR-T 計畫處於臨床開發階段。

本報告分析了全球 CAR-T 細胞治療領域的融資趨勢，包括交易總數和交易金額的趨勢，以及各種類型（融資輪次、IPO、併購交易、我們的交易）的趨勢。調查聯合開發協議、策略合作夥伴關係等詳細趨勢、78家主要公司的交易趨勢以及整個產業的主要驅動因素。

目錄

第 1 章執行摘要

第二章 CAR-T細胞療法在全球的商業化

  • 接受 CAR-T 細胞療法治療的患者總數：依年份（2017-2023 年）
  • FDA 核准的 CAR-T 療法產生的總收入（2017-2023 年）
  • FDA 核准的 CAR-T 療法的標價

第三章 CAR-T 產業融資活動

  • CAR-T產業創投盛會
    • CAR-T公司所募集的創投總額（2014-2023年）
    • CAR-T公司所募集的創投資金：與前一年比較
    • CAR-T 公司所募集的創投（共 78 筆融資）：交易條款與金額

第四章 CAR-T細胞治療公司IPO募集資金

  • CAR-T公司募集的IPO資金：交易條件與金額
    • Juno Therapeutics
    • Cellular Biomedicine Group
    • Xenetic Biosciences
    • Cellular Biomedicine Group
    • Autolus Therapeutics
    • Allogene Therapeutics
    • Precision BioSciences
    • Atara Biotherapeutics
    • Xenetic Biosciences
    • Cabaletta Bio
    • Atara Biotherapeutics
    • Legend Biotech
    • Mustang Bio
    • JW Therapeutics
    • Atara Biotherapeutics
    • Gracell Biotechnologies
    • Vor Biopharma
    • Adicet Bio
    • CARsgen Therapeutics
    • Xenetic Biosciences
    • Caribou Biosciences
    • Celyad Oncology
    • Adicet Bio
    • Legend Biotech
    • Kyverna Therapeutics
    • Arcellx
    • TC Biopharm
    • Celularity
    • TC BioPharm
    • Precision Biosciences
    • Legend Biotech
    • TC Biopharm
    • Vor Biopharma
    • Precigen
    • TC Biopharm
    • Celularity
    • Legend Biotech
    • Coeptis Therapeutics
    • Caribou Biosciences

第五章世界各國CAR-T許可協議實施

  • 全球 CAR-T 許可協議總數
    • CAR-T 授權協議概述：交易條款和金額

第六章 CAR-T業務合作交易

  • CAR-T 相關業務合作（協作）交易（2013-2023 年）
    • 2013年至2023年簽訂的CAR-T業務合作協議概覽

第七章 CAR-T產業併購交易

  • 全球 CAR-T 細胞治療領域執行的併購交易：交易條款與金額
    • Cellular Biomedicine 和 Chinese PLA General Hospital
    • Gilead Sciences 和 Kite Pharma
    • Gilead Sciences 和 Cell Design Labs
    • Novartis 和 Endocyte
    • Bristol Myers Squibb 和 Celgene
    • Xenetic Biosciences 和 Scripps Research Institute
    • Astellas Pharma 和 Xyphos Biosciences
    • BioNTech 和 Neon Therapeutics
    • resTORbio 和 Adicet Bio
    • Century Therapeutics 和 Empirica Therapeutics
    • Celularity 和 GX Acquisition
    • Cellular Biomedicine 和 CBMG Merger Sub
    • Amgen 和 Five Prime Therapeutics
    • BioNTech 和 Kite
    • ImmPACT Bio 和 Kalthera
    • Kiromic Biopharma 和 InSilico Solutions
    • Allogene Therapeutics 和 Antion Biosciences
    • FUJIFILM Corporation 和 Atara Biotherapeutics
    • FUJIFILM Corporation 和 Atara Biotherapeutics
    • Galapagos 和 CellPoint/AboundBio
    • Atossa Therapeutics 和 Dynamic Cell Therapies
    • Kite 和 Tmunity Therapeutics
    • Janssen 和 Cellular Biomedicine
    • Mustang Bio 和 uBriGene Biosciences
    • Precision Biosciences 和 Imugene
    • Oxford Biomedica 和 Institut Merieux
    • Clade Therapeutics 和 Gadeta
    • Kyowa Kirin 和 Orchard Therapeutics

第八章參與募款活動的CAR-T公司概況

  • AdAlta Ltd.
  • Adicet Bio
    • γδT 細胞
  • AffyImmune Therapeutics, Inc.
    • 親和力調整CAR
    • 即時 CAR-T 細胞監測
  • 同種異體療法
    • AlloCAR-T
  • Alpha Biopharma
  • Antion Biosciences
    • miCAR-T技術
  • Arcellx, Inc.
    • D域技術
    • ddCAR
    • ARC-SparX
  • Arsenal Biosciences, Inc.
  • Astellas Pharma, Inc.
    • 合作夥伴關係
  • Atara Biotherapeutics
  • Autolus Therapeutics PLC
  • AvenCell Therapeutics, Inc.
    • 可自由切換的CAR平台
  • Beam Therapeutics
  • Bellicum Pharmaceuticals, Inc.
    • GoCAR技術
    • CaspaCIDe技術
  • Biosceptre
    • 獨特目標：nfP2X7
  • BioNTech SE
    • 基於新抗原的 T 細胞治療平台
  • bluebird bio
  • Cargo Therapeutics
  • Caribou Biosciences, Inc.
    • 下一代 CRISR 技術
    • CAR-T治療平台
  • Carina Biotech
    • LGR5 CAR-T計劃
  • CARsgen Therapeutics Holdings Limited
    • CycloCAR
    • THANK-uCAR
  • Cartherics Pty Ltd
    • Cartherics CAR-T 細胞
  • Cellares
    • Cell Shuttle
  • Cellectis
  • Cellular Biomedicine Group
  • Celularity, Inc.
    • 胎盤的力量
    • NK細胞平台
    • T細胞平台
    • 外泌體平台
  • Celyad 腫瘤學
    • shRNA平台
    • shARC平台
  • Chengdu Usano Biotechnology Co., ltd. (Ucello)
  • Chimeric Therapeutics, Ltd.
    • CLTX CAR-T
    • CDH17 CAR-T
  • Clade Therapeutics
    • 平台技術
  • Coeptis Therapeutics, Inc.
    • SNAP-CAR
  • CRISPR Therapeutics
  • Currus Biologics
    • BEAT 技術
  • CytoMed Therapeutics Ltd.
    • CAR-y delta-T 細胞
  • Dynamic Cell Therapies, Inc.
    • 平台技術
  • Elicera Therapeutics
  • Galapagos NV
  • Gracell Biotechnologies
    • FasTCAR
    • TruUCAR
    • SMART CART
  • EXUMA Biotech Corp.
    • TMR CAR-T技術
  • IASO Biotherapeutics
    • 技術平台
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmPACT Bio
    • CD19/20 雙特異性 CAR
    • TGF-B
  • Inceptor Bio
    • CAR-M療法
  • Interius BioTherapeutics
  • Invectys, Inc.
    • IVS-3001：抗HLA-G CAR-T細胞
  • Juventas Cell Therapy, Ltd.
  • JW Therapeutics
    • Carteyva（勒馬塞爾）
  • 加拉巴哥群島
    • 平台技術
  • Kite Pharma (Gilead)
  • Kyverna Therapeutics
    • "更聰明" 的 CAR-T 細胞
  • Legend Biotech
    • Carvykti
  • Leucid Bio, Ltd
    • 橫向CAR平台
  • Luminary Therapeutics
    • Gamma 2.0+ 平台
  • Lupagen, Inc.
    • 側面 CAR-T 輸送系統
  • MaxCyte, Inc.
  • Minerva Biotechnologies
  • Mustang Bio, Inc.
  • Noile-Immune Biotech
    • PRIME Technology
  • Novartis AG
    • Kymriah 的批准
  • OneChain Immunotherapeutics
  • Oncternal Therapeutics, Inc
  • ROR1　
  • OriCell Therapeutics
    • OriCAR
  • Oxford Biomedica PLC
    • 慢載體平台
    • 腺相關病毒平台
  • Pepromene Bio, Inc.
    • BAFFR CAR-T 細胞
  • PersonGen Bio Therapeutics (Suzhou) Co., Ltd
  • Poseida Therapeutics, Inc.
    • PiggyBac 平台
    • CasCLOVER平台
  • Precigen, Inc.
    • UltraCAR-T 平台
  • 精準生物科學
    • ARCUS基因編輯平台
  • 先見之明療法
    • OmniCAR
    • CellPryme-M
    • CellPryme-A
  • Simnova Biotherapeutics
    • BiTE CAR-T平台
  • SOTIO Biotech B.V.
  • TC BioPharm
    • γδT 細胞
    • T細胞庫
    • Co-Stim CAR-T
  • Umoja 生物製藥
    • VivoVec 體內基因傳遞
    • RACR誘導的細胞毒性淋巴球（iCIL）
    • RACR/CAR體內細胞編程
    • 腫瘤標籤
  • Verismo Therapeutics, Inc.
    • KIR-CAR平台
  • Vor Biopharma
  • Wugen, Inc.
  • Xenetic Biosciences, Inc.
    • XBIO-020：DNase I 裝甲 CAR-T
  • Xyphos Biosciences, Inc.
    • covertibleCAR 技術

圖表列表

表格列表

簡介目錄

EXECUTIVE SUMMARY:

CAR-T industry funding isn't gaining traction, it is surging. At first, the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti have reached the marketplace and created a funding boom. In recent years, CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.

Worldwide, more than 170 companies are engaged in developing CAR-T products and therapies. These CAR-T therapy companies have developed nearly 970 early and late-stage therapies. These companies have also signed an incredible 98 collaboration deals to progress the development of various CAR-T product candidates. Of these, 33 collaboration deals have disclosed their financial terms, which account for a total of $21.7 billion in transactions. If an estimate is made for the collaboration deals that have not disclosed their terms, the total value of these 98 collaboration deals would be in the range of an astonishing $63 billion.

Over the past decade, CAR-T companies have also attracted venture capital investments worth an incredible $6.7 billion, enabling these CAR-T companies to invest in their infrastructure and product pipelines. During the same period, CAR-T companies raised an impressive $5.8 billion through IPO funding to strengthen their technology platforms, clinical trial programs, and corporate efforts.

Within this nascent industry, with over 417,801 patent records and 4,024 granted patents, large pharma has increasingly been seeking to enter the CAR-T field by licensing rights from existing patent owners. Thus, the total value of CAR-T licensing deals over the past decade accounts for another $3.9 billion in transactions and this total is expected to expand substantially in the coming decade.

Among the various financing types analyzed in this report-which include CAR-T industry IPOs, licensing deals, collaborations, strategic partnerships, co-development agreements, and M&A deals-M&A deals constitute the largest financial percentage, accounting for an astounding $95.9 billion over the past decade.

For the nascent CAR-T industry, it is a phenomenal achievement to raise more than $128.25 billion through these various deals that have reported their financial terms. Additionally, 59 of 84 CAR-T licensing deals, 65 of the 98 CAR-T collaboration deals, and 11 of the 27 CAR-T industry M&A deals did not disclose the value of their transactions. Thus, if an approximate estimate is calculated for all deals of undisclosed values, the total value would be a staggering $240 billion.

At present, six CAR-T therapies have been approved by U.S. FDA, including:

  • Tisagenlecleucel-T (Kymriah)
  • Axicabtagene ciloleucel (Yescarta)
  • Brexucabtagene autoleucel (Tecartus)
  • Lisocabtagene maraleucel (Breyanzi)
  • Idecabtagene vicleucel (Abecma)
  • Ciltacabtagene autoleucel (Carvykte)

Many of the CAR-T therapies above have been approved by other regulatory agencies, most commonly for use within the EU. Numerous CAR-T therapies have reached commercialization in other regions as well, such as Relma-cel's (Relmacabtagene) and Yikaida's (Axicabtagene ciloleucel) approval from the NMPA in China, Ebvallo's (tabelecleucel) approval from the European Commission, Actaly-cel's (Actalycabtagene autoleucel) in India, and Fucaso's (Equecabtagene autoleucel) approval in China, for example. This list is not exhaustive because CAR-T approvals are accelerating on a global scale. According to ClinicalTrials.gov, there are also an incredible 706 CAR-T programs that are in clinical phases of development.

This CAR-T market funding report summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events. Of course, it aggregates these numbers so you can understand the global impact of these funding events and how they are propelling rapid growth of the CAR-T sector at large.

It features the following information for the CAR-T cell therapy industry:

  • Financing Rounds
  • IPOs
  • Asset Agreements
  • Strategic Partnerships
  • Co-Development Agreements
  • M&A Transactions
  • Companies Profiles for CAR-T Market Competitors

You can use it to:

  • 1. Quantify CAR-T industry investments
  • 2. Identify well-capitalized companies
  • 3. Scout potential partnerships and alliances
  • 4. Understand partnerships and co-development programs for CAR-T technologies
  • 5. Identify M&A activity within the CAR-T industry

In summary, there have been hundreds of billions of dollars in financial transactions completed by CAR-T companies in recent years. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. GLOBAL COMMERCIALIZATION OF CAR-T CELL THERAPIES

  • 2.1. Total Number of Patients Treated with CAR-T Cell Therapies by Year, 2017-2023
  • 2.2. Total Sales Revenues Generated by FDA-Approved CAR-T Therapies, 2017-2023
  • 2.3. List Prices of FDA-Approved CAR-T Therapies

3. CAR-T INDUSTRY FUNDING EVENTS

  • 3.1. CAR-T Industry Venture Capital Financing Events
    • 3.1.1. Total Venture Capital Raised by CAR-T Companies, 2014 - 2023
    • 3.1.2. Year-Over-Year Comparison of Venture Capital Funding Raised by CAR-T Companies
    • 3.1.3. Venture Capital Raised by CAR-T Companies (78 Capital Raises) - Deal Terms & Values
      • 3.1.3.1. Bellicum Pharmaceuticals
      • 3.1.3.2. CRISPR Therapeutics
      • 3.1.3.3. Autolus
      • 3.1.3.4. Cellular Biomedicine Group
      • 3.1.3.5. Adicet Bio
      • 3.1.3.6. Autolus Limited
      • 3.1.3.7. Cellular Biomedicine Group
      • 3.1.3.8. JW Therapeutics
      • 3.1.3.9. Carina Biotech
      • 3.1.3.10. PeproMene Bio
      • 3.1.3.11. Precision BioSciences
      • 3.1.3.12. Cabaletta Bio
      • 3.1.3.13. Vor Biopharma
      • 3.1.3.14. Gracel Biotechnologies
      • 3.1.3.15. Mustang Bio
      • 3.1.3.16. Poseida Therapeutics
      • 3.1.3.17. BioNTech
      • 3.1.3.18. Adicet Bio
      • 3.1.3.19. Kyverna Therapeutics
      • 3.1.3.20. EXUMA Biotech
      • 3.1.3.21. IASO Biotherapeutics
      • 3.1.3.22. Legend Biotech
      • 3.1.3.23. JW Therapeutics
      • 3.1.3.24. Vor Pharma
      • 3.1.3.25. ImmPACT Bio
      • 3.1.3.26. Synthekine
      • 3.1.3.27. Gracell Biotechnologies
      • 3.1.3.28. CARsgen Therapeutics
      • 3.1.3.29. Umoja Biopharema
      • 3.1.3.30. Juventas Cell Therapy
      • 3.1.3.31. Celyad Oncology
      • 3.1.3.32. Artiva Biotherapeutics
      • 3.1.3.33. Caribou Biosciences
      • 3.1.3.34. Biosceptre
      • 3.1.3.35. Noile-Immune Biotech
      • 3.1.3.36. Arcellx
      • 3.1.3.37. Cellares Corporation
      • 3.1.3.38. Interius BioTherapeutics
      • 3.1.3.39. Synthekine
      • 3.1.3.40. Umoja Biopharma
      • 3.1.3.41. Wugen
      • 3.1.3.42. Mnemo Therapeutics
      • 3.1.3.43. AvenCell
      • 3.1.3.44. Currus Biologics
      • 3.1.3.45. Juventas Cell Therapy
      • 3.1.3.46. Carina Biotech
      • 3.1.3.47. IASO Biotherapeutics
      • 3.1.3.48. Cellular Biomedicines
      • 3.1.3.49. AffyImmune Therapeutics
      • 3.1.3.50. Leucid Bio
      • 3.1.3.51. Clade Therapeutics
      • 3.1.3.52. SOTIO Biotech
      • 3.1.3.53. EXUMA Biotech
      • 3.1.3.54. ImmPACT Bio
      • 3.1.3.55. Kyverna Therapeutics
      • 3.1.3.56. Ucello Therapeutics
      • 3.1.3.57. Mustang Bio
      • 3.1.3.58. Wugen
      • 3.1.3.59. Inceptor Bio
      • 3.1.3.60. Tessa Therapeutics
      • 3.1.3.61. Immuneel Therapeutics
      • 3.1.3.62. OriCell Therapeutics
      • 3.1.3.63. Carina Biotech
      • 3.1.3.64. Juventas Cell Therapy
      • 3.1.3.65. Arsenal Biosciences
      • 3.1.3.66. Synthekine
      • 3.1.3.67. IASO Biotherapeutics
      • 3.1.3.68. MPC Therapeutics
      • 3.1.3.69. OriCell Therapeutics
      • 3.1.3.70. Verismo Therapeutics
      • 3.1.3.71. Cargo Therapeutics
      • 3.1.3.72. OneChain Immunotherapeutics
      • 3.1.3.73. Caribou Biosciences
      • 3.1.3.74. Verismo Therapeutics
      • 3.1.3.75. Kyverna Therapeutics
      • 3.1.3.76. Gracell Biotechnologies
      • 3.1.3.77. Cellares
      • 3.1.3.78. Celyad Oncology

4. IPO FUNDING RAISED BY CAR-T CELL THERAPY COMPANIES

  • 4.1. IPO Funds Raised by CAR-T Compamies - Deal Terms & Values
    • 4.1.1. Juno Therapeutics
    • 4.1.2. Cellular Biomedicine Group
    • 4.1.3. Xenetic Biosciences
    • 4.1.4. Cellular Biomedicine Group
    • 4.1.5. Autolus Therapeutics
    • 4.1.6. Allogene Therapeutics
    • 4.1.7. Precision BioSciences
    • 4.1.8. Atara Biotherapeutics
    • 4.1.9. Xenetic Biosciences
    • 4.1.10. Cabaletta Bio
    • 4.1.11. Atara Biotherapeutics
    • 4.1.12. Legend Biotech
    • 4.1.13. Mustang Bio
    • 4.1.14. JW Therapeutics
    • 4.1.15. Atara Biotherapeutics
    • 4.1.16. Gracell Biotechnologies
    • 4.1.17. Vor Biopharma
    • 4.1.18. Adicet Bio
    • 4.1.19. CARsgen Therapeutics
    • 4.1.20. Xenetic Biosciences
    • 4.1.21. Caribou Biosciences
    • 4.1.22. Celyad Oncology
    • 4.1.23. Adicet Bio
    • 4.1.24. Legend Biotech
    • 4.1.25. Kyverna Therapeutics
    • 4.1.26. Arcellx
    • 4.1.27. TC Biopharm
    • 4.1.28. Celularity
    • 4.1.29. TC BioPharm
    • 4.1.30. Precision Biosciences
    • 4.1.31. Legend Biotech
    • 4.1.32. TC Biopharm
    • 4.1.33. Vor Biopharma
    • 4.1.34. Precigen
    • 4.1.35. TC Biopharm
    • 4.1.36. Celularity
    • 4.1.37. Legend Biotech
    • 4.1.38. Coeptis Therapeutics
    • 4.1.39. Caribou Biosciences

5. CAR-T LICENSING DEALS EXECUTED GLOBALLY

  • 5.1. Total Value of CAR-T Licensing Deals Worldwide
    • 5.1.1. Descriptions of CAR-T Licensing Deals - Deal Terms & Values
      • 5.1.1.1. Cellectis & Ohio State University
      • 5.1.1.2. bluebird bio & Five Prime Therapeutics
      • 5.1.1.3. Poseida Therapeutics & Janssen Biotech
      • 5.1.1.4. bluebird bio & ViroMed
      • 5.1.1.5. Bellicum Pharmaceuticals & Astellas Pharma
      • 5.1.1.6. CRISPR Therapeutics & MaxCyte
      • 5.1.1.7. bluebird bio & Novartis
      • 5.1.1.8. Novartis & Celyad
      • 5.1.1.9. TC Biopharm & University College London (UCL)
      • 5.1.1.10. Mustang Bio & Fred Hutchinson Cancer Research Center
      • 5.1.1.11. Mustang Bio & Harvard University
      • 5.1.1.12. bluebird bio & TC Biopharm
      • 5.1.1.13. Janssen Biotech & Legend Biotech
      • 5.1.1.14. Autolus & UCL Business
      • 5.1.1.15. Otsuka Pharmaceutical & Osaka University
      • 5.1.1.16. Cellular Biomedicine & Novartis
      • 5.1.1.17. CRISPR Therapeutics & MaxCyte
      • 5.1.1.18. Wugen & Washington University
      • 5.1.1.19. Atara Biotherapeutics & Memorial Sloan Kettering Cancer Center
      • 5.1.1.20. bluebird bio & Inhibrx
      • 5.1.1.21. Autolus Therapeutics & Noile-Immune Biotech
      • 5.1.1.22. Vor Biopharma & MaxCyte
      • 5.1.1.23. Juno Therapeutics & Oxford Biomedica
      • 5.1.1.24. Allogene Therapeutics & MaxCyte
      • 5.1.1.25. Kite & Teneobio
      • 5.1.1.26. Legend Biotech & Noile-Immune Biotech
      • 5.1.1.27. Caribou Biosciences & MaxCyte
      • 5.1.1.28. Prescient Therapeutics & University of Pennsylvania
      • 5.1.1.29. Minerva Biotechnologies & Memorial Sloan Kettering Cancer Center
      • 5.1.1.30. Luminary Therapeutics & Case Western Reserve University
      • 5.1.1.31. Beam Therapeutics & Oxford Biomedica
      • 5.1.1.32. SOTIO Biotech & Unum Therapeutics
      • 5.1.1.33. Vor Biopharma & Metagenomi
      • 5.1.1.34. Chimeric Therapeutics & City of Hope
      • 5.1.1.35. Vor Biopharma & Arbor Biotechnologies
      • 5.1.1.36. Immuneel Therapeutics & Hospital Clinic de Barcelona (HCB)
      • 5.1.1.37. Vor Biopharma & National Cancer Institute (NCI)
      • 5.1.1.38. Caribou Biosciences & Memorial Sloan Kettering Cancer Center
      • 5.1.1.39. Carina Biotech & Bionomics
      • 5.1.1.40. Atara Biotherapeutics & Bayer
      • 5.1.1.41. Cellectis & SIRION Biotech
      • 5.1.1.42. Eli Lilly & Precision BioSciences
      • 5.1.1.43. AbbVie & Caribou Biosciences
      • 5.1.1.44. Luminary Therapeutics & Bio-Techne Corporation
      • 5.1.1.45. Wugen & HCW Biologics
      • 5.1.1.46. Alpha Biopharma & Wugen
      • 5.1.1.47. Servier & Precision Biosciences
      • 5.1.1.48. Dr. Reddy's Laboratories & Pregene Biopharma
      • 5.1.1.49. Celularity & MaxCyte
      • 5.1.1.50. BioNTech & Takara Bio
      • 5.1.1.51. Bellicum Pharmaceuticals & UNC Lineberger
      • 5.1.1.52. Mustang Bio & Mayo Clinic
      • 5.1.1.53. Precision Biosciences & Tiziana Sciences
      • 5.1.1.54. Arcellx & Oxford Biomedica
      • 5.1.1.55. Carina Biotech & BayPAT
      • 5.1.1.56. Inceptor Bio & University of California
      • 5.1.1.57. Rebirthel & Otsuka Pharmaceutical
      • 5.1.1.58. Kyverna Therapeutics & National Institutes of Health (NIH)
      • 5.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 5.1.1.60. Antion Biosciences & Allogene Therapeutics
      • 5.1.1.61. Sana Biotechnology & IASO Biotherapeutics
      • 5.1.1.62. CellPoint & Pregene
      • 5.1.1.63. Xenetic Biosciences
      • 5.1.1.64. GO Therapeutics
      • 5.1.1.65. LG Chem & MaxCyte
      • 5.1.1.66. Roche & Poseida Therapeutics
      • 5.1.1.67. Chugai Pharmaceutical & Noile-Immune Biotech
      • 5.1.1.68. Beam Therapeutics & Orbital Therapeutics
      • 5.1.1.69. Undisclosed Company & Oxford Biomedica
      • 5.1.1.70. Coeptis Therapeutics & University of Pittsburgh
      • 5.1.1.71. Cabaletta Bio & IASO Biotherapeutics
      • 5.1.1.72. Inceptor Bio & Avectas
      • 5.1.1.73. Kite Pharma & Refuge Biotechnologies
      • 5.1.1.74. Kite Pharma & Arcellx
      • 5.1.1.75. Cabaletta Bio & Autolus Therapeutics
      • 5.1.1.76. Precigen & Alaunos
      • 5.1.1.77. Leucid Bio & ImaginAb
      • 5.1.1.78. Affini-T Therapeutics & MSK
      • 5.1.1.79. Shunxi Holding & Cartherics
      • 5.1.1.80. Janssen Biotech & Cellular Biomedicine
      • 5.1.1.81. Astellas Pharma & Poseida Therapeutics
      • 5.1.1.82. Imugene & Precision Biosciences
      • 5.1.1.83. Cabaleta Bio & Oxford Biomedica
      • 5.1.1.84. Kyverna Therapeutics & Oxford Biomedica
      • 5.1.1.85. Coeptis Therapeutics & Univerdity of Pittsburgh

6. CAR-T COLLABORATION DEALS

  • 6.1. CAR-T Collaboration Deals between 2013 and 2023
    • 6.1.1. Descriptions of CAR-T Collaboration Deals Signed 2013 to 2023
      • 6.1.1.1. bluebird Bio & Celgene Corporation
      • 6.1.1.2. Pfizer, Inc. & Cellectis
      • 6.1.1.3. Amgen & Kite Pharma
      • 6.1.1.4. Five Prime Therapeutics & bluebird bio
      • 6.1.1.5. Celgene & Juno Therapeutics
      • 6.1.1.6. Cellectis & Servier
      • 6.1.1.7. Kite Pharma & Cell Design Labs
      • 6.1.1.8. Kite Pharma & Fosun Pharma
      • 6.1.1.9. Cellular Biomedicine Group & GE Healthcare Life Sciences, China
      • 6.1.1.10. Novartis & bluebird bio & Celyad
      • 6.1.1.11. Mustang Bio & Harvard University & Beth Israel Deaconess Medical
      • 6.1.1.12. Jenssen Biotech & Legend Biotech
      • 6.1.1.13. PersonGen & Anke Cellular Therapeutics & Miltenyi Biotec
      • 6.1.1.14. Kite Pharma & Sangamo Therapeutics
      • 6.1.1.15. bluebird bio & Celgene Corporation
      • 6.1.1.16. AbbVie & Calibr
      • 6.1.1.17. Novartis & Fraunhofer IZI
      • 6.1.1.18. Cellular Biomedicine & Novartis
      • 6.1.1.19. Regeneron Pharmaceuticals & bluebird bio
      • 6.1.1.20. Cartherics & ToolGen
      • 6.1.1.21. TC Biopharm & Dublin's Trinity College
      • 6.1.1.22. MaxCyte & Kite Pharma
      • 6.1.1.23. Phanes Therapeutics & Phanes Biopharmaceuticals & Fosun Kite
      • 6.1.1.24. Cellectis SA & Servier Monde
      • 6.1.1.25. MaxCyte & Allogene Therapeutics
      • 6.1.1.26. Fate Therapeutics & Janssen Biotech
      • 6.1.1.27. bluebird bio & Bristol Myers Squibb
      • 6.1.1.28. Xenetic Biosciences & PJSC Pharmsynthez
      • 6.1.1.29. Fate Therapeutics & Baylor College of Medicine
      • 6.1.1.30. Beam Therapeutics & Oxford Biomedica
      • 6.1.1.31. Carina Biotech & Glytherix
      • 6.1.1.32. Chimeric Therapeutics & City of Hope
      • 6.1.1.33. Biosceptre & Carina Biotech
      • 6.1.1.34. Allogene Therapeutics & University of Texas MD Anderson Center
      • 6.1.1.35. Oxford Biomedica & PhoreMost Limited
      • 6.1.1.36. Carina Biotech & Bionomics
      • 6.1.1.37. Bayer AG & Atara Biotherapeutics
      • 6.1.1.38. Oncternal Therapeutics & Karolinska Instituet
      • 6.1.1.39. EXUMA Biotech & Moffitt Cancer Center
      • 6.1.1.40. AbbVie & Caribou Biosciences
      • 6.1.1.41. Cytovia Therapeutics & Cellectis SAS
      • 6.1.1.42. JW Therapeutics & Thermo Fisher Scientific
      • 6.1.1.43. AbbVie & Caribou Biosciences
      • 6.1.1.44. Wugen & Alpha Biopharma
      • 6.1.1.45. Dr. Reddy's Laboratories & Shenzhen Pregene Biopharma
      • 6.1.1.46. Vor Biopharma & Abound Bio
      • 6.1.1.47. Kite Pharma & Fosun Pharmaceutical
      • 6.1.1.48. Takara Bio & BioNTech
      • 6.1.1.49. Vor Biopharma & Janssen Biotech
      • 6.1.1.50. Imugene & Celularity
      • 6.1.1.51. Gracell Biotechnologies & FutureGen Biopharm
      • 6.1.1.52. AdAlta & Carina Biotech
      • 6.1.1.53. Celularity & Oncternal Therapeutics
      • 6.1.1.54. Autolus Therapeutics & Blackstone Life Sciences
      • 6.1.1.55. 4basebio & Leucid Bio
      • 6.1.1.56. Leucid Bio & Lonza
      • 6.1.1.57. Oxford Biomedica & Arcellx
      • 6.1.1.58. Carina Biotech & Bayerische Patentallianz (BayPAT)
      • 6.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 6.1.1.60. Arsenal Biosciences & Bristol Myers Squibb
      • 6.1.1.61. Allogene Therapeutics & Antion Biosciences
      • 6.1.1.62. Transgene & PersonGen BioTherapeutics
      • 6.1.1.63. Immatics & Bristol Myers Squibb
      • 6.1.1.64. Legend Biotech & Janssen Biotech
      • 6.1.1.65. Umoja Biopharma & Lupagen
      • 6.1.1.66. Immatics & Celgene
      • 6.1.1.67. Immatics & Bristol Myers Squibb
      • 6.1.1.68. Umoja Biopharma & TreeFrog Therapeutics
      • 6.1.1.69. Invectys & University of Texas Cancer Center
      • 6.1.1.70. Poseida Therapeutics & Roche
      • 6.1.1.71. Chugai Pharmaceutical & Noile-Immune Biotech
      • 6.1.1.72. Kite Pharma & Arcellx
      • 6.1.1.73. Arsenal Biosciences & Genentech
      • 6.1.1.74. Autolus Therapeutics & Bristol Myers Squibb
      • 6.1.1.75. Inceptor Bio & Avectos
      • 6.1.1.76. JW Therapeutics & 2seventy bio
      • 6.1.1.77. Peter MacCallum Cancer Centre and Cartherics
      • 6.1.1.78. Umoja Biopharma & IASO Biotherapeutics
      • 6.1.1.79. Kite Pharma & Arcellx
      • 6.1.1.80. Ori Biotech & Inceptor Bio
      • 6.1.1.81. Simnova & Orna Therapeutics
      • 6.1.1.82. CARsgen Therapeutics & Huadong Medicine
      • 6.1.1.83. TC Biopharm & University of Texas MD Anderson Cancer Center
      • 6.1.1.84. Kite Pharma & Arcellx
      • 6.1.1.85. Peter MacCallum Cancer Centre & Cartherics
      • 6.1.1.86. Cartherics & Shunxi Holding Group
      • 6.1.1.87. Autolus Therapeutics & Cardinal Health
      • 6.1.1.88. Cartherics & Shunxi
      • 6.1.1.89. Janssen Biotech & Cellular Biomedicine
      • 6.1.1.90. CytoMed Therapeutics & University of Texas MD Anderson Cancer
      • 6.1.1.91. Noile-Immune Biotech & Sysmex
      • 6.1.1.92. GenScript Biotech & T-MAXIMUM Biotech
      • 6.1.1.93. CytoMed Therapeutics & Hangzhou CNK Therapeutics
      • 6.1.1.94. CARsgen Therapeutics & Moderna
      • 6.1.1.95. Cellares & Bristol Myers Squibb
      • 6.1.1.96. Celularity & Regeneron Pharmaceuticals
      • 6.1.1.97. Verily & Kyverna Therapeutics
      • 6.1.1.98. Kyverna Therapeutics & Elevate Bio

7. CAR-T INDUSTRY M&A DEALS (MERGER AND ACQUISITION)

  • 7.1. Globally Executed M&A Deals within the CAR-T Cell Therapy Sector - Terms and Values
    • 7.1.1. Cellular Biomedicine & Chinese PLA General Hospital
    • 7.1.2. Gilead Sciences & Kite Pharma
    • 7.1.3. Gilead Sciences & Cell Design Labs
    • 7.1.4. Novartis & Endocyte
    • 7.1.5. Bristol Myers Squibb & Celgene
    • 7.1.6. Xenetic Biosciences & Scripps Research Institute
    • 7.1.7. Astellas Pharma & Xyphos Biosciences
    • 7.1.8. BioNTech & Neon Therapeutics
    • 7.1.9. resTORbio & Adicet Bio
    • 7.1.10. Century Therapeutics & Empirica Therapeutics
    • 7.1.11. Celularity & GX Acquisition
    • 7.1.12. Cellular Biomedicine & CBMG Merger Sub
    • 7.1.13. Amgen & Five Prime Therapeutics
    • 7.1.14. BioNTech & Kite
    • 7.1.15. ImmPACT Bio & Kalthera
    • 7.1.16. Kiromic Biopharma & InSilico Solutions
    • 7.1.17. Allogene Therapeutics & Antion Biosciences
    • 7.1.17. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.18. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.19. Galapagos & CellPoint/AboundBio
    • 7.1.20. Atossa Therapeutics & Dynamic Cell Therapies
    • 7.1.21. Kite & Tmunity Therapeutics
    • 7.1.22. Janssen & Cellular Biomedicine
    • 7.1.23. Mustang Bio & uBriGene Biosciences
    • 7.1.24. Precision Biosciences & Imugene
    • 7.1.25. Oxford Biomedica & Institut Merieux
    • 7.1.26. Clade Therapeutics & Gadeta
    • 7.1.27. Kyowa Kirin & Orchard Therapeutics

8. PROFILES OF CAR-T COMPANIES INVOLVED WITH FUNDING EVENTS

  • 8.1. AdAlta Ltd.
  • 8.2. Adicet Bio
    • 8.2.1. Gamma Delta T Cells
  • 8.3. AffyImmune Therapeutics, Inc.
    • 8.3.1. Affinity-Tuned CARs
    • 8.3.2. Real-Time CAR-T Cell Monitoring
  • 8.4. Allogene Therapeutics
    • 8.4.1. AlloCAR-T
  • 8.5. Alpha Biopharma
  • 8.6. Antion Biosciences
    • 8.6.1. miCAR-T Technology
  • 8.7. Arcellx, Inc.
    • 8.7.1. D-Domain Technology
    • 8.7.2. ddCAR
    • 8.7.3. ARC-SparX
  • 8.8. Arsenal Biosciences, Inc.
  • 8.9. Astellas Pharma, Inc.
    • 8.9.1. Partnering
  • 8.10. Atara Biotherapeutics
  • 8.11. Autolus Therapeutics PLC
  • 8.12. AvenCell Therapeutics, Inc.
    • 8.12.1. Universal Switchable CAR Platform
  • 8.13. Beam Therapeutics
  • 8.14. Bellicum Pharmaceuticals, Inc.
    • 8.14.1. GoCAR Technology
    • 8.14.2. CaspaCIDe Technology
  • 8.15. Biosceptre
    • 8.15.1. The Unique Target: nfP2X7
  • 8.16. BioNTech SE
    • 8.16.1. Neoantigen-based T Cell Therapy Platform
  • 8.17. bluebird bio
  • 8.18. Cargo Therapeutics
  • 8.19. Caribou Biosciences, Inc.
    • 8.19.1. Next-Generation CRISR Technology
    • 8.19.1. CAR-T Therapy Platform
  • 8.20. Carina Biotech
    • 8.20.1. LGR5 CAR-T Program
  • 8.21. CARsgen Therapeutics Holdings Limited
    • 8.21.1. CycloCAR
    • 8.21.2. THANK-uCAR
  • 8.22. Cartherics Pty Ltd
    • 8.22.1. Cartherics' CAR-T Cells
  • 8.23. Cellares
    • 8.23.1. Cell Shuttle
  • 8.24. Cellectis
  • 8.25. Cellular Biomedicine Group
  • 8.26. Celularity, Inc.
    • 8.26.1. Power of the Placenta
    • 8.26.2. NK Cell Platform
    • 8.26.3. T Cell Platform
    • 8.26.4. Exosome Platform
  • 8.27. Celyad Oncology
    • 8.27.1. shRNA Platform
    • 8.27.2. shARC Platform
  • 8.28. Chengdu Usano Biotechnology Co., ltd. (Ucello)
  • 8.29. Chimeric Therapeutics, Ltd.
    • 8.29.1. CLTX CAR-T
    • 8.29.2. CDH17 CAR-T
  • 8.30. Clade Therapeutics
    • 8.30.1. Platform Technologies
  • 8.31. Coeptis Therapeutics, Inc.
    • 8.31.1. SNAP-CAR
  • 8.32. CRISPR Therapeutics
  • 8.33. Currus Biologics
    • 8.33.1. BEAT Technology
  • 8.34. CytoMed Therapeutics Ltd.
    • 8.34.1. CAR-yDelta- T Cell
  • 8.35. Dynamic Cell Therapies, Inc.
    • 8.35.1. Platform Technology
  • 8.36. Elicera Therapeutics
  • 8.37. Galapagos NV
  • 8.38. Gracell Biotechnologies
    • 8.38.1. FasTCAR
    • 8.38.2. TruUCAR
    • 8.38.3. SMART CART
  • 8.39. EXUMA Biotech Corp.
    • 8.39.1. TMR CAR-T Technology
  • 8.40. IASO Biotherapeutics
    • 8.40.1. Technology Platforms
  • 8.41. Immuneel Therapeutics, Pvt., Ltd.
  • 8.42. ImmPACT Bio
    • 8.42.1. CD19/20 Bispecific CAR
    • 8.42.2. TGF-B
  • 8.43. Inceptor Bio
    • 8.43.1. CAR-M Therapies
  • 8.44. Interius BioTherapeutics
  • 8.45. Invectys, Inc.
    • 8.45.1. IVS-3001: Anti HLA-G CAR-T Cells
  • 8.46. Juventas Cell Therapy, Ltd.
  • 8.47. JW Therapeutics
    • 8.47.1. Carteyva (relma-cel)
  • 8.48. Galapagos NV
    • 8.48.1. Platform Technology
  • 8.49. Kite Pharma (Gilead)
  • 8.50. Kyverna Therapeutics
    • 8.50.1. "Smarter" CAR-T Cells
  • 8.51. Legend Biotech
    • 8.51.1. Carvykti
  • 8.52. Leucid Bio, Ltd.
    • 8.52.1. Lateral CAR Platform
  • 8.53. Luminary Therapeutics
    • 8.53.1. Gamma 2.0+ Platform
  • 8.54. Lupagen, Inc.
    • 8.54.1. Side CAR-T Delivery System
  • 8.55. MaxCyte, Inc.
  • 8.56. Minerva Biotechnologies
  • 8.57. Mustang Bio, Inc.
  • 8.58. Noile-Immune Biotech
    • 8.58.1. PRIME Technology
  • 8.59. Novartis AG
    • 8.59.1. Approval of Kymriah
  • 8.60. OneChain Immunotherapeutics
  • 8.61. Oncternal Therapeutics, Inc
  • 8.61. ROR1
  • 8.62. OriCell Therapeutics
    • 8.62.1. OriCAR
  • 8.63. Oxford Biomedica PLC
    • 8.63.1. Lentivector Platform
    • 8.63.2. Adeno-Associated Virus Platform
  • 8.64. Pepromene Bio, Inc.
    • 8.64.1. BAFFR CAR-T Cells
  • 8.65. PersonGen Bio Therapeutics (Suzhou) Co., Ltd
  • 8.66. Poseida Therapeutics, Inc.
    • 8.66.1. PiggyBac Platform
    • 8.66.2. CasCLOVER Platform
  • 8.67. Precigen, Inc.
    • 8.67.1. UltraCAR-T Platform
  • 8.68. Precision BioSciences
    • 8.68.1. ARCUS Gene-Editing Platform
  • 8.69. Prescient Therapeutics
    • 8.69.1. OmniCAR
    • 8.69.2. CellPryme-M
    • 8.69.3. CellPryme-A
  • 8.70. Simnova Biotherapeutics
    • 8.70.1. BiTE CAR-T Platform
  • 8.71. SOTIO Biotech B.V.
  • 8.72. TC BioPharm
    • 8.72.1. Gamma Delta T Cells
    • 8.72.2. T Cell Banks
    • 8.72.3. Co-Stim CAR-T
  • 8.73. Umoja Biopharma
    • 8.73.1. VivoVec In Vivo Gene Delivery
    • 8.73.2. RACR-Induced Cytotoxic Lymphocytes (iCIL)
    • 8.73.3. RACR/CAR In Vivo Cell Programming
    • 8.73.4. TumorTag
  • 8.74. Verismo Therapeutics, Inc.
    • 8.74.1. KIR-CAR Platform
  • 8.75. Vor Biopharma
  • 8.76. Wugen, Inc.
  • 8.77. Xenetic Biosciences, Inc.
    • 8.77.1. XBIO-020: DNase I Armored CAR-T
  • 8.78. Xyphos Biosciences, Inc.
    • 8.78.1. covertibleCAR Technology

INDEX OF FIGURES

  • FIGURE 2.1: Sales Revenues of U.S. FDA-Approved CAR-T Therapies, 2017 to 2023
  • FIGURE 3.1: Total Venture Capital (VC) Raised by CAR-T Companies Worldwide, 2014 to 2023
  • FIGURE 4.1: Total IPO Funds Raised by CAR-T Cell Therapy Companies Worldwide, 2014 to 2023

INDEX OF TABLES

  • TABLE 1.1: All Known CAR-T Fundraising Deals Worldwide, 2014 to Present (Trailing 10 Years)
  • TABLE 2.1: Number of Patients Treated with CAR-T Therapies, 2017 - 2023
  • TABLE 3.1: Venture Capital Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 4.1: IPO Funds Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 5.1: CAR-T Licensing Deals Worldwide, 2015 to Present
  • TABLE 6.1: CAR-T Collaboration Deals Signed Worldwide, 2013 to Present (Trailing 10 Years)
  • TABLE 7.1: CAR-T M&A Deals Signed Worldwide, 2015 to Present